Repatha is named as an intervention in 4 current clinical trials in our China, France, Italy and South Korea registers. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is General Hospital of Shenyang Military Region (1). The most-studied condition is Hypertriglyceridemia Induced Acute Pancreatitis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
NCT05430828 · ClinicalTrials.gov ↗ · Hypercholesterolemia
|
Observational | Recruiting | Federico II University | Italy |
|
Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis
NCT07388420 · ClinicalTrials.gov ↗ · Hypertriglyceridemia Induced Acute Pancreatitis
|
Not applicable | Recruiting | General Hospital of Shenyang Military Region | China |
|
Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI
NCT04951856 · ClinicalTrials.gov ↗ · STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
|
Phase 4 | Active, closed | Assistance Publique - Hôpitaux de Paris | France |
|
Evolocumab in STEMI
NCT06081803 · ClinicalTrials.gov ↗ · ST Elevation Myocardial Infarction
|
Phase 3 | Active, closed | Sejong General Hospital | South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Federico II University | 1 |
| Sejong General Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Italy | 1 | 1 |
| Clinical trials in South Korea | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China, France, Italy and South Korea registers name Repatha as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 1 with sites in China and 1 with sites in Italy. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
General Hospital of Shenyang Military Region (1), Assistance Publique - Hôpitaux de Paris (1), Federico II University (1) and Sejong General Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Repatha works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Repatha works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Repatha (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.